30% off. Use code SUMMER30 at checkout for 30% off for 12 months on Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Terns Pharmaceuticals Inc (TERN)

Track

Over the last 90 days, Terns Pharmaceuticals Inc. has seen significant insider selling, with a net value of -$993,858.90. The Chief Executive Officer and Chief Medical Officer have been the primary sellers. There were no insider purchases during this period. The company's stock has experienced a 19.5% increase in the last 90 days.
Stock chart
Ticker: TERN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Kuriakose Emil
Chief Medical Officer
2 sales — total 99,386 USD
Sale 1 Apr 2026
Value US$2,340,080.27 | Price 101.31 | Shares 92,834
Sale 1 Apr 2026
Value US$4,660,355.31 | Price 174.38 | Shares 28,556
Planned sale 16 Mar 2026
Value US$457,016.93 | Price 62.38 | Shares 72,575
Planned sale 16 Mar 2026
Value US$2,213,769.05 | Price 330.98 | Shares 33,752
Planned sale 17 Feb 2026
Value US$162,501.36 | Price 39.80 | Shares 4,083
Planned sale 17 Feb 2026
Value US$319,963.34 | Price 39.22 | Shares 8,159
Planned sale 17 Feb 2026
Value US$89,114.38 | Price 38.07 | Shares 2,341
Planned sale 15 Jan 2026
Value US$282,230.04 | Price 37.53 | Shares 7,521
Planned sale 15 Jan 2026
Value US$2,266,372.79 | Price 37.02 | Shares 61,228
Proposed sale 15 Jan 2026
Value US$3,640,479.70 | Price 37.18 | Shares 97,915
Sale 5 Jan 2026
Value US$2,718,229.92 | Price 38.10 | Shares 71,339
Sale 2 Jan 2026
Value US$36,632.46 | Price 38.36 | Shares 955
Sale 2 Jan 2026
Value US$7,920.00 | Price 39.60 | Shares 200
Planned sale 4 Nov 2025
Value US$441,360.00 | Price 18.00 | Shares 24,520
Proposed sale 4 Nov 2025
Value US$344,015.60 | Price 14.03 | Shares 24,520
Sale 1 Oct 2025
Value US$7,407.00 | Price 7.85 | Shares 944
Sale 1 Jul 2025
Value US$3,639.84 | Price 4.27 | Shares 853
Buy 27 Jun 2025
Value US$19,649.50 | Price 3.93 | Shares 5,000
Buy 27 Jun 2025
Value US$19,633.50 | Price 3.93 | Shares 5,000
Planned buy 25 Jun 2025
Value US$90,229.84 | Price 3.87 | Shares 23,314
Buy 16 Jun 2025
Value US$19,732.50 | Price 3.95 | Shares 5,000
Buy 13 Jun 2025
Value US$18,600.00 | Price 3.72 | Shares 5,000
Buy 13 Jun 2025
Value US$18,750.00 | Price 3.75 | Shares 5,000
Sale 1 Apr 2025
Value US$2,365.82 | Price 2.49 | Shares 952
Proposed sale 6 Jan 2025
Value US$52,089.25 | Price 5.75 | Shares 9,059
Proposed sale 6 Jan 2025
Value US$50,370.00 | Price 5.75 | Shares 8,760
Planned sale 6 Jan 2025
Value US$50,758.07 | Price 5.79 | Shares 8,760
Planned sale 6 Jan 2025
Value US$52,499.62 | Price 5.80 | Shares 9,059
Sale 2 Jan 2025
Value US$35,702.16 | Price 5.72 | Shares 6,240
Sale 2 Jan 2025
Value US$46,523.89 | Price 5.72 | Shares 8,129
Sale 2 Jan 2025
Value US$25,607.12 | Price 5.71 | Shares 4,481
Planned buy 5 Dec 2024
Value US$110,467.50 | Price 7.15 | Shares 15,450
Planned buy 30 Nov 2024
Value US$11,497.50 | Price 5.11 | Shares 2,250
Planned buy 30 Nov 2024
Value US$2,606.10 | Price 5.11 | Shares 510
Buy 12 Sep 2024
Value US$2,999,997.00 | Price 10.50 | Shares 285,714
Buy 12 Sep 2024
Value US$1,999,998.00 | Price 10.50 | Shares 190,476
Planned sale 10 Sep 2024
Value US$110,000.00 | Price 11.00 | Shares 10,000
Proposed sale 10 Sep 2024
Value US$91,200.00 | Price 9.12 | Shares 10,000
Proposed sale 10 Sep 2024
Value US$91,200.00 | Price 9.12 | Shares 10,000
Planned sale 9 Sep 2024
Value US$172,350.00 | Price 10.00 | Shares 17,235
Proposed sale 9 Sep 2024
Value US$69,173.17 | Price 7.81 | Shares 8,857
Planned sale 2 Aug 2024
Value US$66,431.93 | Price 7.50 | Shares 8,857
Sale 1 Aug 2024
Value US$47,148.14 | Price 7.68 | Shares 6,143
Sale 16 Jul 2024
Value US$6,230.00 | Price 10.00 | Shares 623
Sale 16 Jul 2024
Value US$5,560.00 | Price 10.00 | Shares 556
Sale 16 Jul 2024
Value US$40,090.00 | Price 10.00 | Shares 4,009
Sale 16 Jul 2024
Value US$6,230.00 | Price 10.00 | Shares 623
Sale 16 Jul 2024
Value US$5,560.00 | Price 10.00 | Shares 556
Sale 16 Jul 2024
Value US$40,090.00 | Price 10.00 | Shares 4,009
Planned sale 16 Jul 2024
Value US$4,000.00 | Price 10.00 | Shares 400
Sale 15 Jul 2024
Value US$61,420.00 | Price 10.00 | Shares 6,142
Sale 15 Jul 2024
Value US$54,010.00 | Price 10.00 | Shares 5,401
Sale 15 Jul 2024
Value US$394,330.00 | Price 10.00 | Shares 39,433
Sale 15 Jul 2024
Value US$61,420.00 | Price 10.00 | Shares 6,142
Sale 15 Jul 2024
Value US$54,010.00 | Price 10.00 | Shares 5,401
Sale 15 Jul 2024
Value US$394,330.00 | Price 10.00 | Shares 39,433
Planned sale 15 Jul 2024
Value US$143,660.06 | Price 10.00 | Shares 14,365
Proposed sale 15 Jul 2024
Value US$297,920.00 | Price 9.31 | Shares 32,000
Proposed sale 15 Jul 2024
Value US$1,226,127.00 | Price 9.31 | Shares 131,700
Proposed sale 15 Jul 2024
Value US$9,094,008.00 | Price 9.31 | Shares 976,800
Proposed sale 15 Jul 2024
Value US$1,418,844.00 | Price 9.31 | Shares 152,400
Planned buy 31 May 2024
Value US$21,272.04 | Price 4.44 | Shares 4,791
Planned buy 31 May 2024
Value US$21,272.04 | Price 4.44 | Shares 4,791
Proposed sale 3 Apr 2024
Value US$32,658.00 | Price 6.00 | Shares 5,443
Proposed sale 3 Apr 2024
Value US$236,496.00 | Price 6.00 | Shares 39,416
Proposed sale 3 Apr 2024
Value US$817,548.00 | Price 6.00 | Shares 136,258
Planned sale 3 Apr 2024
Value US$25,723.80 | Price 6.20 | Shares 4,149
Planned sale 3 Apr 2024
Value US$186,291.40 | Price 6.20 | Shares 30,047
Planned sale 3 Apr 2024
Value US$643,994.00 | Price 6.20 | Shares 103,870
Planned sale 2 Apr 2024
Value US$20,282.50 | Price 6.65 | Shares 3,050
Planned sale 2 Apr 2024
Value US$146,858.60 | Price 6.65 | Shares 22,084
Planned sale 2 Apr 2024
Value US$507,700.90 | Price 6.65 | Shares 76,346
Planned sale 1 Apr 2024
Value US$38,102.49 | Price 6.99 | Shares 5,451
Planned sale 1 Apr 2024
Value US$275,482.89 | Price 6.99 | Shares 39,411
Planned sale 1 Apr 2024
Value US$952,422.45 | Price 6.99 | Shares 136,255
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-02 2026-04-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
92,834 -15.0%
101.31
US$2,340,080 		92,834 -15.0% 101.31 US$2,340,080
2026-04-02 2026-04-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
28,556 -44.9%
174.38
US$4,660,355 		28,556 -44.9% 174.38 US$4,660,355
2026-03-17 2026-03-16 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
72,575 -22.5%
62.38
US$457,017 		72,575 -22.5% 62.38 US$457,017
2026-03-17 2026-03-16 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
11,813 -3.9%
46.57
US$550,081 		11,813 -3.9% 46.57 US$550,081
2026-02-18 2026-02-17 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
4,083 -1.4%
39.80
US$162,501 		4,083 -1.4% 39.80 US$162,501
2026-02-18 2026-02-17 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
8,159 -2.7%
39.22
US$319,963 		8,159 -2.7% 39.22 US$319,963
2026-02-18 2026-02-17 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
2,341 -0.8%
38.07
US$89,114 		2,341 -0.8% 38.07 US$89,114
2026-01-16 2026-01-15 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
7,521 -2.5%
37.53
US$282,230 		7,521 -2.5% 37.53 US$282,230
2026-01-16 2026-01-15 PlS Planned sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
61,228 -17.1%
37.02
US$2,266,373 		61,228 -17.1% 37.02 US$2,266,373
2026-01-15 2026-01-15 PrS Proposed sale
3.0
AMY BURROUGHS

Director; Officer

Executive Director
97,915
37.18
US$3,640,480 		97,915 37.18 US$3,640,480
2026-01-06 2026-01-05 S Sale
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
71,339 -33.9%
38.10
US$2,718,230 		71,339 -33.9% 38.10 US$2,718,230
2026-01-06 2026-01-02 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
955 -1.9%
38.36
US$36,632 		955 -1.9% 38.36 US$36,632
2026-01-06 2026-01-02 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
200 -0.4%
39.60
US$7,920 		200 -0.4% 39.60 US$7,920
2025-11-05 2025-11-04 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
24,520 -100.0%
18.00
US$441,360 		24,520 -100.0% 18.00 US$441,360
2025-11-04 2025-11-04 PrS Proposed sale
3.7
JILL QUIGLEY

Director

Non-Executive Director
24,520
14.03
US$344,016 		24,520 14.03 US$344,016
2025-10-02 2025-10-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
944 -1.8%
7.85
US$7,407 		944 -1.8% 7.85 US$7,407
2025-07-03 2025-07-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
853 -1.6%
4.27
US$3,640 		853 -1.6% 4.27 US$3,640
2025-06-30 2025-06-27 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +25.0%
3.93
US$19,650 		5,000 +25.0% 3.93 US$19,650
2025-06-30 2025-06-27 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +33.3%
3.93
US$19,634 		5,000 +33.3% 3.93 US$19,634
2025-06-25 2025-06-25 PP Planned purchase
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
23,314 +98.1%
3.87
US$90,230 		23,314 +98.1% 3.87 US$90,230
2025-06-16 2025-06-16 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +50.0%
3.95
US$19,732 		5,000 +50.0% 3.95 US$19,732
2025-06-16 2025-06-13 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +100.0%
3.72
US$18,600 		5,000 +100.0% 3.72 US$18,600
2025-06-16 2025-06-13 B Purchase
1.9
Gengos Andrew

Chief Financial Officer

Officer
5,000 +inf%
3.75
US$18,750 		5,000 +inf% 3.75 US$18,750
2025-04-02 2025-04-01 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
952 -1.8%
2.49
US$2,366 		952 -1.8% 2.49 US$2,366
2025-01-06 2025-01-06 PrS Proposed sale
3.3
MARK J VIGNOLA

Officer

Officer
9,059
5.75
US$52,089 		9,059 5.75 US$52,089
2025-01-06 2025-01-06 PrS Proposed sale
3.7
JILL QUIGLEY

Director

Non-Executive Director
8,760
5.75
US$50,370 		8,760 5.75 US$50,370
2025-01-06 2025-01-06 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
8,760 -100.0%
5.79
US$50,758 		8,760 -100.0% 5.79 US$50,758
2025-01-06 2025-01-06 PlS Planned sale
3.3
Vignola Mark J.

Chief Financial Officer

Officer
9,059 -10.8%
5.80
US$52,500 		9,059 -10.8% 5.80 US$52,500
2025-01-06 2025-01-02 S Sale
3.7
Quigley Jill M.
Non-Executive Director
6,240 -41.6%
5.72
US$35,702 		6,240 -41.6% 5.72 US$35,702
2025-01-06 2025-01-02 S Sale
3.3
Vignola Mark J.

Chief Financial Officer

Officer
8,129 -8.8%
5.72
US$46,524 		8,129 -8.8% 5.72 US$46,524
2025-01-06 2025-01-02 S Sale
2.4
Kuriakose Emil

Chief Medical Officer

Officer
4,481 -7.6%
5.71
US$25,607 		4,481 -7.6% 5.71 US$25,607
2024-12-09 2024-12-05 PP Planned purchase
3.0
Burroughs Amy L.

Chief Executive Officer

Executive Director
15,450 +423.4%
7.15
US$110,468 		15,450 +423.4% 7.15 US$110,468
2025-02-03 2024-11-30 PP Planned purchase Jung Melita Sun

Chief Business Officer

Officer
2,250 +inf%
5.11
US$11,498 		2,250 +inf% 5.11 US$11,498
2025-02-03 2024-11-30 PP Planned purchase Burroughs Amy L.

Chief Executive Officer

Executive Director
510 +2.7%
5.11
US$2,606 		510 +2.7% 5.11 US$2,606
2024-09-17 2024-09-12 B Purchase
3.4
Lu Hongbo
Non-Executive Director
285,714 +150.0%
10.50
US$2,999,997 		285,714 +150.0% 10.50 US$2,999,997
2024-09-17 2024-09-12 B Purchase
3.4
Lu Hongbo
Non-Executive Director
190,476 +inf%
10.50
US$1,999,998 		190,476 +inf% 10.50 US$1,999,998
2024-09-12 2024-09-10 PlS Planned sale
3.3
Vignola Mark J.

Chief Financial Officer

Officer
10,000 -9.8%
11.00
US$110,000 		10,000 -9.8% 11.00 US$110,000
2024-09-10 2024-09-10 PrS Proposed sale
SEOKHO BRYAN YOON

Officer

Officer
10,000
9.12
US$91,200 		10,000 9.12 US$91,200
2024-09-10 2024-09-10 PrS Proposed sale
3.3
MARK J VIGNOLA

Officer

Officer
10,000
9.12
US$91,200 		10,000 9.12 US$91,200
2024-09-11 2024-09-09 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
17,235 -53.5%
10.00
US$172,350 		17,235 -53.5% 10.00 US$172,350
2024-09-09 2024-09-09 PrS Proposed sale
3.7
JILL QUIGLEY

Officer

Officer
8,857
7.81
US$69,173 		8,857 7.81 US$69,173
2024-08-05 2024-08-02 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
8,857 -37.1%
7.50
US$66,432 		8,857 -37.1% 7.50 US$66,432
2024-08-05 2024-08-01 S Sale
3.7
Quigley Jill M.
Non-Executive Director
6,143 -20.5%
7.68
US$47,148 		6,143 -20.5% 7.68 US$47,148
2024-07-17 2024-07-16 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
623 -0.1%
10.00
US$6,230 		623 -0.1% 10.00 US$6,230
2024-07-17 2024-07-16 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
556 -0.0%
10.00
US$5,560 		556 -0.0% 10.00 US$5,560
2024-07-17 2024-07-16 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
4,009 -0.1%
10.00
US$40,090 		4,009 -0.1% 10.00 US$40,090
2024-07-17 2024-07-16 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
623 -0.1%
10.00
US$6,230 		623 -0.1% 10.00 US$6,230
2024-07-17 2024-07-16 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
556 -0.0%
10.00
US$5,560 		556 -0.0% 10.00 US$5,560
2024-07-17 2024-07-16 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
4,009 -0.1%
10.00
US$40,090 		4,009 -0.1% 10.00 US$40,090
2024-07-17 2024-07-16 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
400 -1.3%
10.00
US$4,000 		400 -1.3% 10.00 US$4,000
2024-07-17 2024-07-15 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
6,142 -0.8%
10.00
US$61,420 		6,142 -0.8% 10.00 US$61,420
2024-07-17 2024-07-15 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
5,401 -0.3%
10.00
US$54,010 		5,401 -0.3% 10.00 US$54,010
2024-07-17 2024-07-15 S Sale
1.5
GORDON CARL L
Non-Executive Director Large shareholder
39,433 -0.8%
10.00
US$394,330 		39,433 -0.8% 10.00 US$394,330
2024-07-17 2024-07-15 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
6,142 -0.8%
10.00
US$61,420 		6,142 -0.8% 10.00 US$61,420
2024-07-17 2024-07-15 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
5,401 -0.3%
10.00
US$54,010 		5,401 -0.3% 10.00 US$54,010
2024-07-17 2024-07-15 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
39,433 -0.8%
10.00
US$394,330 		39,433 -0.8% 10.00 US$394,330
2024-07-17 2024-07-15 PlS Planned sale
3.7
Quigley Jill M.
Non-Executive Director
14,365 -32.4%
10.00
US$143,660 		14,365 -32.4% 10.00 US$143,660
2024-07-15 2024-07-15 PrS Proposed sale
3.7
JILL QUIGLEY

Director; Officer

Executive Director
32,000
9.31
US$297,920 		32,000 9.31 US$297,920
2024-07-15 2024-07-15 PrS Proposed sale
2.6
OrbiMed Asia Partners III, LP

Director; Shareholder

Non-Executive Director
131,700
9.31
US$1,226,127 		131,700 9.31 US$1,226,127
2024-07-15 2024-07-15 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Director; Shareholder

Non-Executive Director
976,800
9.31
US$9,094,008 		976,800 9.31 US$9,094,008
2024-07-15 2024-07-15 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, LP

Director; Shareholder

Non-Executive Director
152,400
9.31
US$1,418,844 		152,400 9.31 US$1,418,844
2024-06-04 2024-05-31 PP Planned purchase
3.3
Vignola Mark J.

Chief Financial Officer

Officer
4,791 +5.5%
4.44
US$21,272 		4,791 +5.5% 4.44 US$21,272
2024-06-04 2024-05-31 PP Planned purchase
Yoon Seokho Bryan

COO and General Counsel

Officer
4,791 +5.5%
4.44
US$21,272 		4,791 +5.5% 4.44 US$21,272
2024-04-03 2024-04-03 PrS Proposed sale
Vivo Capital Surplus Fund VIII, L.P.

Director

Non-Executive Director
5,443
6.00
US$32,658 		5,443 6.00 US$32,658
2024-04-03 2024-04-03 PrS Proposed sale
Vivo Capital Fund VIII, L.P.

Director

Non-Executive Director
39,416
6.00
US$236,496 		39,416 6.00 US$236,496
2024-04-03 2024-04-03 PrS Proposed sale
Vivo Opportunity Fund Holdings, L.P.

Director

Non-Executive Director
136,258
6.00
US$817,548 		136,258 6.00 US$817,548
2024-04-03 2024-04-03 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
4,149 -1.5%
6.20
US$25,724 		4,149 -1.5% 6.20 US$25,724
2024-04-03 2024-04-03 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
30,047 -1.5%
6.20
US$186,291 		30,047 -1.5% 6.20 US$186,291
2024-04-03 2024-04-03 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
103,870 -2.5%
6.20
US$643,994 		103,870 -2.5% 6.20 US$643,994
2024-04-03 2024-04-02 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
3,050 -1.1%
6.65
US$20,282 		3,050 -1.1% 6.65 US$20,282
2024-04-03 2024-04-02 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
22,084 -1.1%
6.65
US$146,859 		22,084 -1.1% 6.65 US$146,859
2024-04-03 2024-04-02 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
76,346 -1.8%
6.65
US$507,701 		76,346 -1.8% 6.65 US$507,701
2024-04-03 2024-04-01 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
5,451 -1.9%
6.99
US$38,102 		5,451 -1.9% 6.99 US$38,102
2024-04-03 2024-04-01 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
39,411 -1.9%
6.99
US$275,483 		39,411 -1.9% 6.99 US$275,483
2024-04-03 2024-04-01 PlS Planned sale
2.8
Vivo Opportunity, LLC
Large shareholder
136,255 -3.1%
6.99
US$952,422 		136,255 -3.1% 6.99 US$952,422
Explore more

More insider trading research around Terns Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America